Articles by Daniel Marsh
GameStop's $9 Billion War Chest Fuels Stock Rally
GameStop shares climbed to $26.61 as the market speculates on CEO Ryan Cohen's strategy for the company's $9 billion cash pile. Q4 results revealed a sales decline but improved operating income.
Veeva Systems Joins S&P 500, Stock Jumps 10.5%
Veeva Systems shares jumped 10.5% to $172.29 after S&P Dow Jones Indices announced the company will join the S&P 500 on May 7, replacing Coterra Energy.
Summit Therapeutics Shares Dive 23% After HARMONi-3 Update Disappoints
Summit Therapeutics shares plummeted 23% after an interim HARMONi-3 update for ivonescimab failed to show early benefit. The trial remains blinded, with final PFS data due in late 2026.
iSpecimen Shares Swing Wildly After 1-for-40 Reverse Stock Split
ISPC shares tumbled 8.2% to $4.80 Friday after a volatile week, as the company's 1-for-40 reverse split aimed to boost its stock price above Nasdaq's $1 minimum bid by a May 18 deadline.
Wolfspeed Rallies on Stake Disclosure and Executive Shakeup Ahead of Earnings
Wolfspeed shares jumped after a group tied to Susquehanna disclosed a 5% stake. New executives and debt refinancing signal turnaround efforts before earnings.
Esperion to Be Acquired by ARCHIMED in $1.1 Billion Deal, Shares Jump 56%
ARCHIMED will acquire Esperion Therapeutics for $3.16 per share in cash plus contingent value rights, valuing the deal at up to $1.1 billion. Esperion shares surged 56% on the news.
Rivian Shares Dip as Reduced Georgia Loan Casts Shadow on R2 SUV Ambitions
Rivian shares slid 5.7% after a reduced federal loan for its Georgia factory raised questions about its R2 SUV strategy. The company reported Q1 revenue of $1.38 billion and a narrowed net loss.
Spirit Airlines Faces Imminent Closure After $500M Federal Rescue Fails
Spirit Airlines is preparing to shut down after failing to secure a $500 million U.S. bailout, jeopardizing over 17,000 jobs and billions in claims.
Ciena Shares Face Valuation Check as $416 Target Highlights Priced-In AI Hopes
Ciena shares face a valuation reality check after Rothschild & Co Redburn set a $416 target, nearly 22% below the current price, as much of the AI networking optimism appears already priced in.
Cue Biopharma Rockets 91% on Allergy Drug License, CEO Change, and $30M Capital Raise
Cue Biopharma shares soared 91.4% after licensing Ascendant-221, a Phase 2 anti-IgE antibody, naming Shao-Lee Lin as CEO, and raising $30 million.